Grifols announced that its Chronos‑PD program has produced proof‑of‑concept data showing that biological changes associated with Parkinson’s disease can be detected more than a decade before clinical diagnosis. The program, run by the company’s subsidiary Alkahest, analyzed over 2,600 longitudinal plasma samples and identified reproducible early‑stage biomarkers, including a novel CXCL12‑cell adhesion‑integrin axis linked to neuroinflammation.
The findings, published in medRxiv, demonstrate that the Chronos platform can track disease progression from the pre‑clinical phase, with data indicating detection up to 12 years before diagnosis. The platform’s AI‑driven proteomics analysis of 25,000 protein types across 15 years of samples provides a unique, large‑scale view of Parkinson’s biology that could inform future diagnostics and therapeutics.
The study was funded by a $21 million grant from the Michael J. Fox Foundation for Parkinson’s Research and will be presented at the AD/PD 2026 conference in Copenhagen, scheduled for March 17‑21 2026. The results were also posted to medRxiv, making them publicly available ahead of the conference.
Grifols’ broader strategy is to leverage its plasma‑derived biopharma expertise for precision medicine. By establishing an early‑detection framework for a major neurodegenerative disease, the company positions itself to expand its research portfolio beyond plasma products and potentially open new revenue streams in diagnostics and targeted therapies. The Chronos program draws on Grifols’ extensive plasma repository of over 100 million samples, giving it a competitive advantage in biomarker discovery.
"Despite decades of research and treatment advancement, the understanding of the drivers of the disease remains limited. This new proof‑of‑concept data offers additional insights into the biology and progression of PD, years before clinical detection. The results also validate the Chronos platform, with potential applications beyond PD. Going back in time to search for the earliest signs of disease can help accelerate and ultimately develop new diagnostics and disease‑modifying therapeutics," said Dr. Jörg Schüttrumpf, Grifols Chief Scientific Innovation Officer.
"Chronos reframes early disease detection by shifting from symptom‑based evaluation to molecular trajectory profiling, offering a powerful foundation for accelerating the development of early detection and intervention tools at population scale," added Benoit Lehallier, PhD, Principal Investigator of Chronos and Sr. Director of Data Science at Alkahest.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.